{
    "id": "wrong_mix_property_subsidiary_00045_1",
    "rank": 10,
    "data": {
        "url": "https://synapse.patsnap.com/organization/bbc5fe68369d38a0223445bb4a014033",
        "read_more_link": "",
        "language": "en",
        "title": "Drug pipelines, Patents, Clinical trials",
        "top_image": "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/bbc5/fe68/369d/38a0/2234/45bb/4a01/4033/4d433be1e960c26a_48w.webp",
        "meta_img": "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/bbc5/fe68/369d/38a0/2234/45bb/4a01/4033/4d433be1e960c26a_48w.webp",
        "images": [
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/bbc5/fe68/369d/38a0/2234/45bb/4a01/4033/4d433be1e960c26a_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/dcbb/161c/0ffb/5ed6/91f3/90f4/fc34/a921/670552d18fe20187_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/bbc5/fe68/369d/38a0/2234/45bb/4a01/4033/4d433be1e960c26a_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/9597/e75b/a30c/9958/d433/1f58/6407/d7cf/22228693a2508212_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/4d0e/408a/2a62/df7a/401f/ecda/4fdb/812b/65326e0827981540_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/6e7a/2de7/0d46/daa0/cef8/586c/a22a/e506/8be8f6721a6327f6_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/f62c/0b43/2f09/6ed2/a6c5/f859/9fd4/fbff/03bde6bac22edafd_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/org_logo/prod/COMPANY/MASTER/LOGO/9b88/7e67/e08f/4f52/0a3e/ae17/7d6e/e451/4b8a532a290b623c_48w.webp",
            "https://synapse-tour.cdn.patsnap.com/synapse/open_resource/news_image/prod/data/news/image/5fc8/450f/00e3/2d2e/5fc8450f00e32d2e.jpeg",
            "https://synapse-static.patsnap.com/ssr/7d5f7b2e/_nuxt/en-corp-tree.1891d746.png",
            "https://synapse-static.patsnap.com/ssr/7d5f7b2e/_nuxt/en-drug-deal.78729d7c.png",
            "https://synapse-static.patsnap.com/ssr/7d5f7b2e/_nuxt/en-translational-medicine.b428d8c3.png",
            "https://synapse-static.patsnap.com/ssr/7d5f7b2e/_nuxt/en-profit.e8449358.png",
            "https://synapse-static.patsnap.com/ssr/7d5f7b2e/_nuxt/en-funding.a5fdebb5.png",
            "https://synapse-static.patsnap.com/ssr/7d5f7b2e/_nuxt/en-investment.6a82dd7e.png",
            "https://synapse-static.patsnap.com/ssr/7d5f7b2e/_nuxt/en-financing.27c56893.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Genzyme Corp.",
            "Mavorixafor",
            "Fidanacogene elaparvovec",
            "Nirsevimab",
            "NASDAQ: GENZ"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Explore Genzyme Corp. with its drug pipeline, therapeutic area, technology platform, 720 clinical trials, 471 news, and 2 literature, Disease Domain:Endocrinology and Metabolic Disease, Nervous System Diseases, Immune System Diseases, Neoplasms, Hemic and Lymphatic Diseases, Infectious Diseases, Technology Platform:Small molecule drug, Monoclonal antibody, Enzyme, Hormone, AAV based gene therapy, Drug:Isatuximab-IRFC, Teriflunomide, Cross-linked Sodium Hyaluronate, Insulin lispro biosimilar (Sanofi), Insulin Glulisine Recombinant.",
        "meta_lang": "en",
        "meta_favicon": "/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://synapse.patsnap.com/organization/bbc5fe68369d38a0223445bb4a014033",
        "text": "Introduction\n\nSanofi Genzyme is a global business unit of Sanofi that specializes in rare diseases, multiple sclerosis, immunology, and oncology. Their mission is to help individuals with challenging and complex conditions that are often difficult to diagnose and treat. The company is committed to discovering and advancing new therapies to provide hope to patients and their families worldwide. Genzyme became a part of Sanofi in 2011 and has since expanded its focus to include multiple sclerosis, oncology, and immunology. Their approach is shaped by a long history of developing highly specialized treatments and building strong relationships with physician and patient communities. Founded in 1981, Genzyme quickly became one of the world's leading biotechnology companies, known for its pioneering work in treating rare genetic disorders and innovative contributions to medical science and biomanufacturing."
    }
}